{
  "pmcid": "6326436",
  "sha256": "b108df5b15b72543b2c74ca71be5839527ad32048e54e1ee07345c0363846c34",
  "timestamp_utc": "2025-11-09T22:49:53.739440+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.886090026478378,
    "reading_ease": 40.86197705207417,
    "word_count": 206
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Papaverine Concentrations for Vasospasm Prevention in Radial Artery Grafts"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In a randomised controlled trial, RA segments were harvested from 10 CABG patients at John Paul II Hospital."
      },
      "Participants": {
        "score": 2,
        "evidence": "RA segments were harvested from 10 CABG patients at John Paul II Hospital."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The segments were randomly assigned to two groups: 0.5 mg/ml papaverine (n=12) and 2 mg/ml papaverine (n=12)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy of two papaverine concentrations (0.5 mg/ml and 2 mg/ml) for vasospasm prevention and their impact on endothelial integrity in radial artery (RA) grafts used in coronary artery bypass graft (CABG) surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was vasodilatory effect, assessed using ex vivo myography over 60 minutes."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "The segments were randomly assigned to two groups."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The segments were randomly assigned to two groups: 0.5 mg/ml papaverine (n=12) and 2 mg/ml papaverine (n=12)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 2 mg/ml papaverine group showed stronger vasodilatation (mean difference = 24.67%, 95% CI 15.23 to 34.11; p < 0.001) but caused more endothelial damage (mean difference = 22.63%, 95% CI 8.91 to 36.35; p = 0.002) compared to the 0.5 mg/ml group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}